Name-Centric Gender Inference Using Data Analytics

Pudaruth, Sameerchand; Singh, Upasana; Ramnial, Hoshiladevi

doi:10.1109/iscmi.2016.44

Cited by 2 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the gender mapping algorithm and manual lookups are imperfect, our approach is consistent with prior work in this area 16,47 . Unisex names posed a particular challenge 48 . It should be noted that we could not account for all situations where an author changed their name (e.g., a person assumed their spouse's surname); this could have led to overestimation of representation by women and underestimation of impact, since this practice is more common with women.…”

Section: Discussionmentioning

confidence: 99%

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Sigworth

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Clinical trials establish the standard of cancer care, yet the evolution and characteristics of the social dynamics between the people conducting this work remain understudied. We performed a social network analysis of authors publishing chemotherapy-based prospective trials from 1946 to 2018 to understand how social influences, including the role of gender, have influenced the growth and development of this network, which has expanded exponentially from fewer than 50 authors in 1946 to 29,197 in 2018. While 99.4% of authors were directly or indirectly connected by 2018, our results indicate a tendency to predominantly connect with others in the same or similar fields, as well as an increasing disparity in author impact and number of connections. Scale-free effects were evident, with small numbers of individuals having disproportionate impact. Women were under-represented and likelier to have lower impact, shorter productive periods (P < 0.001 for both comparisons), less centrality, and a greater proportion of co-authors in their same subspecialty. The past 30 years were characterized by a trend towards increased authorship by women, with new author parity anticipated in 2032. The network of cancer clinical trialists is best characterized as strategic or mixed-motive, with cooperative and competitive elements influencing its appearance. Network effects such as low centrality, which may limit access to high-profile individuals, likely contribute to the observed disparities.

show abstract

Section: Discussionmentioning

confidence: 99%

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Sigworth

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…34,41 Unisex names posed a particular challenge. 42 It should be noted that we could not account for all situations where an author changed their name (e.g., a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. not certified by peer review) (which was The copyright holder for this preprint this version posted November 2, 2019. .…”

Section: Discussionmentioning

confidence: 99%

“…34,41 Unisex names posed a particular challenge. 42 It should be noted that we could not account for all situations where an author changed their name (e.g., a person assumed their spouse’s surname); this could have led to overestimation of representation by women and underestimation of impact, since this practice is more common with women. It is also possible that an individual’s gender identity does not match the gender assignment of their given name.…”

Section: Discussionmentioning

confidence: 99%

Seven Decades of Chemotherapy Clinical Trials: A Pan-Cancer Social Network Analysis

Sigworth

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Clinical trials establish the standard of care for cancer and other diseases. While social network analysis has been applied to basic sciences, the social component of clinical trial research is not well characterized. We examined the social network of cancer clinical trialists and its dynamic development over more than 70 years, including the roles of subspecialization and gender in relation to traditional and network-based metrics of productivity. Methods: We conducted a social network analysis of authors publishing chemotherapy-based prospective trials from 1946-2018, based on the curated knowledge base HemOnc.org, examining: 1) network density; 2) modularity; 3) assortativity; 4) betweenness centrality; 5) PageRank; and 6) the proportion of co-authors sharing the same primary cancer subspecialty designation. Individual author impact and productive period were analyzed as a function of gender and subspecialty. Findings: From 1946-2018, the network grew to 29,197 authors and 697,084 co-authors. While 99.4% of authors were directly or indirectly connected as of 2018, the network had very few connections and was very siloed by cancer subspecialty. Small numbers of individuals were highly connected and had disproportionate impact (scale-free effects). Women were under-represented and likelier to have lower impact, shorter productive periods (P<0.001 for both comparisons), less centrality, and a greater proportion of co-authors in their same subspecialty. The past 30 years were characterized by a trend towards increased authorship by women, with new author parity anticipated in 2032. However, women remain a distinct minority of first/last authors, with parity not anticipated for 50+ years. Interpretation: The network of cancer clinical trialists is best characterized as a strategic or "mixed-motive" network, with cooperative and competitive elements influencing its appearance. Network effects e.g., low centrality, which may limit access to high-profile individuals, likely contribute to ongoing disparities. Funding: Vanderbilt Initiative for Interdisciplinary Research; National Institutes of Health; National Science Foundation

show abstract

Name-Centric Gender Inference Using Data Analytics

Cited by 2 publications

References 4 publications

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Seven Decades of Chemotherapy Clinical Trials: A Pan-Cancer Social Network Analysis

Contact Info

Product

Resources

About